← The Wire
TBPHNasdaq
Theravance Biopharma, Inc.
Pharmaceutical Preparations · CA · CIK 1583107
Theravance Biopharma develops and commercializes medicines, earning revenue from collaborations and licensing
red 8-K · 90d⚡ Elevated coverage
$858M
Market cap
$17.06
Last close
-3.2%
1D
+3.0%
5D
3.1M
Volume
Price · last 39 sessions+0.9%
May 4L $15.58 · H $17.63Jun 29
261
Total filings
Jun 29, 2026
Last filing
12/31
Fiscal year end
DEFA14ADEFA14AJun 29, 20268-KMaterial Agreement · Reg FD DisclosureJun 29, 20268-KExecutive ChangeJun 23, 20268-KShareholder VoteJun 12, 202610-Q10-QMay 7, 20268-KResults of OperationsMay 7, 2026DEF 14ADEF 14AApr 28, 20268-KCompany UpdateMar 30, 2026SC 13D/ASC 13D/AMar 25, 202610-K10-KMar 23, 20268-KResults of OperationsMar 19, 20268-KResults of Operations · Exit / Disposal CostsMar 3, 20268-KReg FD DisclosureJan 12, 20268-KCompany UpdateDec 8, 202510-Q10-QNov 12, 20258-KResults of OperationsNov 10, 20258-KCompany UpdateAug 25, 20258-KCompany UpdateAug 20, 202510-Q10-QAug 13, 20258-KResults of OperationsAug 12, 20258-KCompany UpdateJun 26, 20258-KCompany UpdateJun 6, 20258-KMaterial Agreement · Acquisition / DispositionJun 2, 20258-KShareholder VoteMay 20, 202510-Q10-QMay 12, 20258-KResults of OperationsMay 8, 2025DEF 14AFORM-DEF 14AApr 10, 202510-K10-KMar 7, 20258-KResults of OperationsFeb 26, 202510-Q10-QNov 14, 20248-KResults of OperationsNov 12, 20248-KCompany UpdateSep 23, 20248-KReg FD DisclosureSep 10, 2024SC 13GSC 13GAug 16, 202410-Q10-QAug 8, 20248-KResults of OperationsAug 5, 202410-Q10-QMay 15, 20248-KResults of OperationsMay 13, 20248-KShareholder VoteMay 9, 2024DEF 14ADEF 14AApr 5, 202410-K10-KMar 1, 20248-KCompany UpdateFeb 28, 20248-KResults of OperationsFeb 26, 2024SC 13GSC 13GFeb 14, 20248-KCompany UpdateJan 16, 20248-KCompany UpdateJan 5, 20248-KCompany UpdateDec 28, 2023DEFA14ADEFA14ADec 21, 20238-KExecutive Change · Material AgreementDec 21, 202310-Q10-QNov 9, 20238-KExecutive Change · Results of OperationsNov 7, 20238-KCompany UpdateOct 30, 20238-KReg FD DisclosureSep 12, 202310-Q10-QAug 9, 20238-KResults of OperationsAug 7, 20238-KAgreement TerminatedJun 9, 202310-Q/A10-Q/AMay 18, 202310-Q10-QMay 10, 20238-KResults of OperationsMay 8, 20238-KExecutive Change · Security-Holder RightsMay 3, 20238-KReg FD DisclosureApr 17, 2023SC 13DSC 13DApr 12, 2023DEFA14ADEFA14AApr 11, 2023DEFA14ADEFA14AApr 11, 20238-KExecutive Change · Company UpdateApr 11, 2023DEF 14ADEF 14AMar 28, 20238-KReg FD DisclosureMar 13, 202310-K10-KMar 1, 20238-K/AExecutive ChangeMar 1, 2023DEFA14ADEFA14AFeb 28, 2023DEFA14ADEFA14AFeb 28, 20238-KCompany UpdateFeb 28, 20238-KExecutive Change · Results of OperationsFeb 27, 20238-KResults of OperationsJan 9, 20238-KExecutive ChangeDec 12, 20228-K/ACompany UpdateNov 14, 202210-Q10-QNov 9, 20228-KResults of OperationsNov 7, 20228-KReg FD DisclosureNov 3, 20228-KCompany UpdateSep 20, 2022
Insider Activity
In the 90 days to Mar 16, 2026: 1 sold $434K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 16, 2026 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sell | 15,534 | $14.00 | $217K |
| Mar 16, 2026 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sell | 7,767 | $13.92 | $108K |
| Mar 16, 2026 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sell | 7,766 | $13.92 | $108K |
| Dec 3, 2025 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sell | 15,534 | $18.75 | $291K |
| Dec 3, 2025 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sell | 7,767 | $18.75 | $146K |
| Dec 3, 2025 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sell | 7,766 | $18.75 | $146K |
| Nov 26, 2025 | Broshy EranDirector | Sell | 15,501 | $20.00 | $310K |
| Nov 26, 2025 | Broshy EranDirector | Sell | 14,000 | $20.00 | $280K |
| Nov 11, 2025 | Broshy EranDirector | Sell | 29,500 | $18.50 | $546K |
| Nov 11, 2025 | Broshy EranDirector | Sell | 15,500 | $18.50 | $287K |
| Nov 11, 2025 | Broshy EranDirector | Sell | 15,500 | $17.00 | $264K |
| Nov 11, 2025 | Broshy EranDirector | Sell | 15,500 | $17.00 | $264K |
| Nov 11, 2025 | Broshy EranDirector | Sell | 14,000 | $18.50 | $259K |
| Nov 11, 2025 | Broshy EranDirector | Sell | 14,000 | $18.50 | $259K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
⚡ Elevated coverageCoverage (30d): 2 reputable articles · skews ▲ positive.
ReutersZymeworks expands beyond cancer with $929 million Theravance acquisition22h agoBarron'sZymeworks to Buy Theravance for Lung Disease Drug. Both Stocks Are Sliding.1d ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance